FindTrial
Sign In

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221965
Enrollment
Unknown
Registered
2012-11-19
Start date
2012-11-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor

Interventions

investigational material(s) Generic name etc : LY2157299 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational materia

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Have solid tumor. - Have adequate hematologic, hepatic and renal function. - Have a performance status of higher than or equal to 1 on the Eastern Cooperative Oncology Group scale. - Able to swallow tablets.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026